C ardiac amyloidosis is caused by deposition of amyloid fibrils from misfolded proteins, most commonly, circulating immunoglobulin light chains (light chain amyloidosis [AL]) or transthyretin proteins (transthyretin amyloidosis [ATTR]). 1, 2 In patients with heart failure, cardiac amyloidosis is suspected by typical morphological features on imaging, and the diagnosis is confirmed by endomyocardial biopsy. 3 By the time cardiac amyloidosis is apparent on echocardiography or cardiac MRI, the disease is at a fairly advanced stage and less likely to respond to specific antiamyloid therapy. 3 An urgent need exists to identify cardiac amyloidosis at an earlier stage and longitudinally track response to therapy.
See Clinical Perspective
Because of recent breakthroughs in molecular imaging, cardiac amyloid deposits can, for the first time, be imaged using amyloid-binding radiopharmaceuticals. Preliminary clinical studies suggest that 11 C-Pittsburgh B compound 4 and 18 F-florbetapir 5 are promising molecular imaging biomarkers for AL and ATTR cardiac amyloidosis. The 2 plausible explanations for increased myocardial radiotracer uptake in patients with cardiac amyloidosis are longer tissue transit of radiotracer because of expanded extracellular volume of distribution and direct binding of the radiotracer to cardiac amyloid fibrils. In vitro autoradiography studies, in subjects with Alzheimer's disease have confirmed binding of amyloid radiotracers to small amounts of β-amyloid in brain tissue. 6 But the precise mechanism of increased amyloid radiotracer
Background-
18 F-florbetapir is a promising imaging biomarker for cardiac light chain amyloidosis (AL) and transthyretin amyloidosis (ATTR). Our aim, using human autopsy myocardial specimens, was to test the hypothesis that 18 F-florbetapir binds specifically to myocardial AL and ATTR amyloid deposits. Methods and Results-We studied myocardial sections from 30 subjects with autopsy-documented AL (n=10), ATTR (n=10), and nonamyloid controls (n=10) using 18 F-florbetapir and cold florbetapir compound and digital autoradiography. Total and nonspecific binding of 18 F-florbetapir was determined using the maximum signal intensity values. Specific binding of 18 F-florbetapir was calculated by subtracting nonspecific from total binding measurements (in decays per minute/mm 2 , DPM mm 2 ) and was compared with cardiac structure and function on echocardiography and the histological extent of amyloid deposits. Diffuse or focally increased 18 F-florbetapir uptake was noted in all AL and ATTR samples and in none of the control samples. Compared with control samples, mean uptake in patients with cardiac AL or ATTR amyloidosis is not yet certain.
Our primary goal, using human myocardial specimens from autopsy, was to test the hypothesis that 18 F-florbetapir specifically binds to myocardial AL and ATTR amyloid deposits. We also explored (1) the differential binding affinity of 18 F-florbetapir in AL and ATTR samples, as reported in a pilot human study 5 and (2) the incremental value of 18 F-florbetapir autoradiography, over echocardiography, to identify early cardiac amyloid deposits.
Methods
We determined specific binding of 18 F-florbetapir to human myocardial AL and ATTR amyloid deposits, in vitro, using autoradiography. Subjects with autopsies performed between 2005 and 2013 at Brigham and Women's Hospital, a tertiary care medical center and a national referral center for cardiac amyloidosis, were included. Our study cohort included 20 random subjects with myocardial amyloidosis on histology, typed into AL (n=10) or ATTR (n=10) amyloid by immunohistochemistry or mass spectroscopy as needed. We also included myocardial samples from a control group of 10 subjects with nonamyloid cardiac pathologies. The clinical history and laboratory evaluation of all the amyloid subjects were recorded by a detailed review of electronic medical records. The study was approved by the Partners Human Research Committee (protocol # 2014P000384).
Echocardiography
Clinically obtained 2-dimensional (2D) echocardiograms were batch processed (18/20); 1 subject did not have an echocardiogram at our institution, and 1 study was limited because of images obtained during cardiopulmonary resuscitation. Increased left ventricular (LV) wall thickness (>11 mm) was considered a typical echocardiographic feature consistent with amyloidosis. The LV mass was calculated as recommended by the American Society of Echocardiography (ASE). 7 Digitally acquired echocardiography images in Digital Imaging and Communications in Medicine (DICOM) format were uploaded and processed using vendor independent offline 2D Cardiac Performance Analysis software (Tom Tec Imaging System, Munich, Germany) to compute peak systolic tissue Doppler-based LV longitudinal strain values in 16 subjects. Only data on global LV longitudinal strain were used for this analysis.
Histopathology
A 5-µm-thick cross section of LV myocardium was studied from each of the hearts with histologically documented AL (n=10) and ATTR (n=10) amyloidosis and nonamyloid hearts (n=10). The nonamyloid hearts (control) were either histologically normal or displayed pathologies, including interstitial fibrosis, acute myocardial infarction, healing myocardial infarction with inflammation, or remote myocardial infarction with replacement fibrosis. Standard histological sections were stained with hematoxylin and eosin, Congo red, sulfated Alcian blue, and Masson's trichrome stain for morphological evaluation. The percent cross-sectional area of total interstitial and perivascular amyloid was estimated visually as a percentage (extent of amyloid) using the sulfated Alcian blue stains by 2 independent readers, with discordant reads resolved by consensus. Histological slides were scanned at ×1 using a Nikon CoolScan 5000 for correlation with autoradiographic images.
Autoradiography Methods
Unstained histological sections were deparaffinized in xylene and progressively rehydrated through graded ethanols to normal saline using standard methods. All 30 sections were incubated together for 1 hour with 0.1 nmol/L The sections were washed 2 times in 40% ethanol and dried for an hour. The slides were then placed on a phosphor plate (Kodak SO230) which was exposed overnight (14 hours). A 50-µm resolution digital image of the autoradiography was obtained using a phosphor reader (Bio-Rad, Personal Molecular Imager system).
Quantification of

18
F-Florbetapir Uptake
Quantitative measurements of signal intensity in 18 F-florbetapir autoradiography images were performed using ImageJ (National Institutes of Health). To avoid tissue areas with nonuniform thickness, edge effect, or other sectioning artifacts, we drew a region of interest (ROI) that is smaller than the tissue size and well within the boundary of tissue (Figure 1 ). The size of ROI varied on each section depending on the size of the tissue and included at least 40% of the tissue. The same sized ROI was used for total binding and nonspecific binding images. Using 2 standard sources with known activity, we converted the digital image pixel values (counts) in arbitrary units into number of decay per minute (DPM) per unit area, DPM/mm 2 . The conversion factor was 50.6 counts/DPM. The 18 F-florbetapir signal intensity in DPM/mm 2 within the ROI was used in this analysis.
Evaluation of Total and Nonspecific Binding of 18 F-Florbetapir
Total and nonspecific binding of 18 F-florbetapir was determined using the maximum and the mean signal intensity values from the ROI for each subject and reported as DPM/mm 2 . We subtracted nonspecific binding measurements from total binding measurements and calculated the logarithmic value of the difference as specific binding. For all analyses in this article, unless specified otherwise, the average values of maximum 18 F-florbetapir-specific binding was analyzed and reported as specific binding. Also, 3 observers systematically compared and visually colocalized the 18 F-florbetapir uptake and location on the autoradiography images to amyloid deposits on the histology slides in the 30 samples.
Statistical Analysis
The data are presented as frequencies, percentages, mean±SD, and medians with interquartile range as appropriate. 18 F-florbetapirspecific binding is reported as mean±SD. 
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uptake of the 20 amyloid and 10 nonamyloid samples was compared using a Student t test; a P value of <0.05 was considered as a significant difference. We used ANOVA with post hoc Bonferroni test for 3-way comparisons (AL versus ATTR versus controls). We used univariable analyses to predict the determinants of the histological extent of myocardial amyloid. To determine the independent predictors of the extent of myocardial amyloid, we developed a parsimonious multivariable linear regression model forcing into the model a history of systemic AL amyloidosis, LV mass, mean LV longitudinal strain, and 18 F-florbetapir uptake. The criterion for entry into the model was 0.05, and the criterion for removal was 0.10.
Results
The baseline clinical characteristics of the AL and ATTR amyloid and control subjects are listed in Table 1 . The ATTR subjects were older, more likely to be men, and had a higher frequency of paced rhythm. The rest of the clinical characteristics did not differ between the AL and the ATTR subjects. In 13 subjects (65%), a clinical diagnosis of cardiac amyloidosis was documented based on clinical history and biopsy combined with a classic echocardiogram before the autopsy. In the remaining subjects, myocardial amyloid deposits were identified at autopsy.
The AL and the ATTR subjects also demonstrated similar echocardiographic characteristics ( Table 2 ). The median interval between echocardiogram and autopsy was 14 days (interquartile range, 7-202 days), and the echocardiograms were typical for amyloidosis (wall thickness >11 mm) in 14 of 18 subjects. 18 
Distribution and Colocalization of
F-Florbetapir and Amyloid Deposits
The overall cardiac pathology and cause of death in the entire study cohort are presented in Table 3 . On histopathology, most of the amyloid samples showed varying extents of diffuse interstitial amyloid deposits; however, distinct focal vascular amyloid deposits with minimal interstitial deposition were noted in a few samples. On autoradiography, Figure 4A ), and the range (40% versus 70%; Figure 4A ) of amyloid extent was narrower with AL compared with the ATTR samples. Despite a trend to lower amyloid extent, 18 F-florbetapir-specific binding per unit amyloid extent (average value of mean 18 F-florbetapir specific binding) was significantly higher in AL samples compared with ATTR samples (Figure 4B ).
Univariable and Multivariable Correlates of Extent of Myocardial Amyloid
Univariable analyses were performed to determine the imaging correlates of the histological extent of myocardial amyloid. We found that increased LV wall thickness, increased LV mass, and decreased mean LV longitudinal strain significantly correlated directly with greater extent of myocardial amyloid (Table 4 ). There was no correlation between the Congestive heart failure AL indicates light chain amyloidosis; ATTR, transthyretin amyloidosis; and PEA, pulseless electrical activity. *The section was from an area of heart not involved by the infarction. 
Incremental Value of 18 F-Florbetapir-Specific Binding in Subjects With Atypical Echocardiograms
As shown in Figure 5A and 5B, even subjects with small and focal amyloid deposits (ATTR=3 and AL=1) without increased LV wall thickening demonstrated increased 18 F-florbetapir-specific binding was consistently and significantly higher in amyloid compared with control myocardium. Notably, although, 18 F-florbetapir bound to both AL and to ATTR amyloid, specific binding was significantly higher to AL than to ATTR amyloid. This is a novel finding, as none of the current radiotracers can reliably image myocardial AL amyloid. Finally, myocardial samples from subjects with atypical echocardiograms revealed a significantly higher 18 F-florbetapirspecific binding compared with control samples suggesting a potential role in early diagnosis. 18 F-florbetapir 5 and 11 C-PiB 4, 8 have been used to successfully image AL and ATTR cardiac amyloidosis in pilot human studies. Our study confirms high specific binding of 
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18 F-florbetapir in myocardial AL and ATTR amyloid deposits. The current study results extend results from an Alzheimer's disease autoradiography study showing that 18 F-florbetapir binds accurately to minute amounts of β-amyloid 9 and that uptake correlates with the density of β-amyloid plaques. 6, 9 As 18 F-florbetapir bound to small amounts of cardiac amyloid fibrils, independent of the precursor protein, it may become a valuable screening tool for the detection of cardiac AL and ATTR amyloidosis. 18 F-florbetapir-specific binding was consistently and significantly higher in amyloid compared with control myocardial samples supporting a high specificity. The control myocardial samples showed low level background 18 F-florbetapir nonspecific uptake. But, that is unlikely to be an issue for in vivo imaging, as relative or absolute myocardial 18 F-florbetapir uptake is not interpreted in isolation, but, compared with the blood pool/liver uptake (target/background ratio). In a recent human study, the target/background standardized uptake value ratio distinguished subjects with amyloidosis from those without. 5 
High
18 F-florbetapir-specific binding to AL compared with ATTR amyloid in vitro is a novel finding of our study. Based on these findings, one could hypothesize that in vitro, the concentration of available binding sites for 18 F-florbetapir may be different in AL and ATTR amyloid fibrils, either because of differences in protein conformation or the binding region. However, there was significant overlap; as observed by in vivo human studies, 5 the degree of 18 F-florbetapir-specific binding did not distinguish AL from ATTR amyloid deposits.
High specific binding to AL amyloid is an important finding because few of the existing radiotracers can consistently image myocardial AL amyloidosis. 10-12 123 I serum amyloid P component, an amyloid tracer, is not helpful in the heart because of limited signal/noise ratio.
99m
Tc aprotinin is an amyloid-binding tracer that can image AL amyloid. But, it is not widely available, shows limited signal in the heart and is not used clinically because of concerns of bovine spongiform encephalitis (as it is produced from bovine lungs).
14 Intense uptake of bone imaging agents, Tcpyrophosphate( 99m Tc-PYP), is accurate to diagnose cardiac ATTR amyloidosis likely because of high calcium levels in the amyloid deposits. 15,16 99m Tc-DPD and 99m Tc-PYP are widely available and intense radiotracer uptake is highly specific for diagnosing cardiac ATTR amyloidosis. 10 Their value for 
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diagnosing early cardiac involvement with ATTR is, however, unclear. Also, they do not reliably image AL amyloidosis. [10] [11] [12] Thus, dual isotope imaging combining 18 F-florbetapir and bone imaging agents could conceivably become a novel protocol to identify cardiac amyloid and to type it. Furthermore, radiotracer-based molecular imaging of amyloidosis may be complementary to late gadolinium enhancement and ECV expansion on cardiac MRI: the presence and the type of amyloidosis can be identified. For instance, we had a recent subject with monoclonal gammopathy of uncertain significance, cardiac MRI strongly suggested cardiac amyloidosis, but could not distinguish between AL and ATTR. A Tc-99 m PYP SPECT was negative; but 18 F-florbetapir positron emission tomography was strongly positive confirming myocardial AL amyloidosis. A sensitive noninvasive diagnostic test can potentially limit the use of endomyocardial biopsy to subjects with documented cardiac amyloidosis improving the risk versus benefit for endomyocardial biopsy, an invasive procedure. Furthermore, being noninvasive, targeted amyloid imaging offers the potential to screen high-risk individuals for cardiac amyloidosis; early disease detection may be possible, for the first time.
Myocardial samples from subjects with atypical echocardiograms revealed greater 18 F-florbetapir-specific uptake compared with control samples. Small amounts of TTR-derived amyloid deposits are common in aging hearts, but the clinical significance, if any, is unclear. However, recent autopsy-based data suggest that they may contribute to diastolic dysfunction, 17 and our findings suggest that 18 F-florbetapir imaging may offer a possible imaging technique in patients for addressing this. Novel antiamyloid chemotherapies for reducing light chain burden 18 and microRNA-based therapies for reducing transthyretin amyloid formation, 19 offer a potential for cure, if used before extensive amyloid deposition in the heart. Therefore, early disease detection is important. Clinically significant focal myocardial deposits, whether AL or TTR, which may occasionally be missed on endomyocardial biopsy because of sampling error, may also be better detected by 18 F-florbetapir imaging. Further clinical studies, especially those correlating 18 F-florbetapir with endomyocardial biopsy prospectively, are warranted.
Study Limitations
We performed a cross-sectional in vitro autoradiography imaging study to demonstrate that 18 F-florbetapir specifically binds to cardiac amyloid deposits, but these findings may not exactly reflect in vivo tracer uptake. Competition assays, with varying concentrations of cold florbetapir, would identify if 18 F-florbetapir binding affinity varies for AL versus ATTR amyloidosis, but are beyond the scope of this work. In addition to establishing specific binding to myocardial AL and ATTR amyloid deposits, the lack of focal myocardial uptake in the control samples with interstitial fibrosis, myocardial infarction, and replacement fibrosis and in a TTR amyloid sample with metastatic melanoma supports specificity of myocardial 18 F-florbetapir uptake to amyloid fibrils.
Conclusions
18 F-florbetapir specifically binds to myocardial AL and ATTR amyloid deposits in humans. 18 F-florbetapir demonstrates substantially greater specific binding, in vitro, to myocardial AL compared with ATTR amyloid deposits. These autoradiography data support the premise that specific binding of 18 F-florbetapir to AL and ATTR fibrils forms the mechanistic basis for increased myocardial 18 F-florbetapir uptake observed in patients with cardiac amyloidosis. Our findings provide a foundation to consider clinical trials, using 18 F-florbetapir, to screen for early cardiac AL and ATTR amyloidosis and to quantify changes in cardiac amyloid deposits in response to anti amyloid therapies.
